Clinical Trial

Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced Mesothelioma

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective, single-arm, multicenter, phase II clinical trial designed to evaluate the efficacy and safety of iparomlimab and tuvoraleimab in combination with bevacizumab and chemotherapy as first-line treatment for advanced mesothelioma.
Trial Details
NCT Number NCT07514793
Lead Sponsor Fudan University
Conditions Mesothelioma
Enrollment 37 participants
Start Date 2026-04
Primary Completion 2029-04 (estimated)
Study Completion 2029-04 (estimated)
Updated on ClinicalTrials.gov 2026-04-07